Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Source: View publication →
The DESTINY-Breast04 trial established trastuzumab deruxtecan as a new standard of care for patients with HER2-low metastatic breast cancer, demonstrating superior progression-free and overall survival compared to standard chemotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
DESTINY-Breast04 is a landmark trial that redefined the HER2-low population as a distinct, actionable category for HER2-targeted therapy. By demonstrating that an antibody-drug conjugate (trastuzumab deruxtecan) is superior to standard physician's choice chemotherapy in patients with HER2-low metastatic disease, the trial has fundamentally shifted the treatment paradigm for a large subset of breast cancer patients who were previously classified as HER2-negative.
Historical Context
Historically, HER2 status was strictly classified as either 'positive' (requiring HER2-directed therapy) or 'negative' (not requiring HER2-targeted therapy). The 'HER2-low' category, representing tumors with IHC 1+ or IHC 2+/ISH- expression, was excluded from HER2-targeted approaches. This trial provided the definitive evidence required to move beyond binary HER2 categorization, validating the use of specialized antibody-drug conjugates to exploit lower levels of target protein expression.
Guided Discussion
High-yield insights from every perspective
What is the unique 'bystander effect' mechanism of Trastuzumab Deruxtecan (T-DXd), and why does it allow this drug to be effective in HER2-low tumors while earlier agents like T-DM1 were not?
Key Response
Unlike T-DM1, T-DXd utilizes a highly membrane-permeable topoisomerase I inhibitor payload and a high drug-to-antibody ratio. When the drug is internalized and the payload is released in a HER2-expressing cell, the payload can cross the cell membrane to kill adjacent tumor cells regardless of their HER2 expression levels. This is critical in HER2-low cancers where HER2 expression is often heterogeneous.
In the management of a patient starting T-DXd based on the DESTINY-Breast04 protocol, which specific adverse event requires the most vigilant monitoring due to its potential for high-grade toxicity, and what are the standard management steps if it is suspected?
Key Response
Interstitial Lung Disease (ILD)/pneumonitis is the most significant toxicity (occurring in 12.1% of patients in the trial). Management involves proactive monitoring for cough, dyspnea, or fever, regular CT scans, and immediate discontinuation of the drug for even Grade 1 symptoms, typically followed by systemic corticosteroid administration.
The DESTINY-Breast04 trial included a small cohort of patients with hormone receptor (HR)-negative, HER2-low disease. How do these results influence the treatment sequencing for patients traditionally classified as 'Triple-Negative' Breast Cancer (TNBC)?
Key Response
The trial showed a significant PFS and OS benefit even in the HR-negative cohort (PFS 8.5 vs 2.9 months). This effectively redefines a subset of TNBC as HER2-low, placing T-DXd as a preferred later-line option, potentially competing with or following Sacituzumab Govitecan in the treatment algorithm for these patients.
With the establishment of HER2-low as a clinically actionable therapeutic category, how does this study challenge our current reliance on the binary IHC classification system (0 vs. 1+), and what are the implications for patients previously labeled as IHC 0?
Key Response
The study creates a therapeutic 'gold rush' for IHC 1+ and 2+ results, but IHC was originally optimized to identify high expression (3+), not to distinguish 0 from 1+. This highlights the need for more sensitive assays (like quantitative proteomics or digital imaging) to identify 'HER2-ultralow' patients who might still benefit from the bystander effect but are currently excluded based on outdated binary scoring.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of 'Physician's Choice' as the control arm in DESTINY-Breast04. How might the heterogeneity of the control treatments (capecitabine, eribulin, gemcitabine, etc.) affect the interpretation of the hazard ratios for progression-free survival?
Key Response
While 'Physician's Choice' reflects real-world clinical practice and increases the trial's external validity, it introduces variability in the control arm's efficacy. If the distribution of selected chemotherapies was imbalanced or if certain agents were less effective in the HER2-low population, it could potentially inflate the perceived benefit of T-DXd compared to a single, more potent comparator.
As a reviewer, what concerns would you raise regarding the reproducibility of the 'HER2-low' designation given the documented 30-50% inter-pathologist discordance in distinguishing IHC 0 from IHC 1+?
Key Response
The primary threat to the study's validity is the lack of a standardized, highly reproducible assay for the lower end of the HER2 spectrum. If the 'HER2-low' status is not reliably reproducible across different labs, the generalizability of the trial's efficacy to the broader clinical population is compromised, as many 'IHC 0' patients might actually be 'IHC 1+' and vice-versa.
Based on the OS benefit demonstrated in DESTINY-Breast04, how should the NCCN and ASCO guidelines be updated for HR-positive metastatic breast cancer that has progressed on endocrine therapy and at least one line of chemotherapy?
Key Response
Current guidelines have been updated to include T-DXd as a Category 1 recommendation for HER2-low patients in the second-line or later setting. The strength of the OS data (17.5 months vs 13.9 months in the HR+ cohort) justifies moving T-DXd ahead of standard single-agent chemotherapies (like eribulin or capecitabine) for patients who meet the IHC 1+ or 2+/ISH-negative criteria.
Clinical Landscape
Noteworthy Related Trials
EMILIA Trial
Tested
Trastuzumab emtansine (T-DM1)
Population
HER2-positive advanced breast cancer patients previously treated with trastuzumab and a taxane
Comparator
Capecitabine plus lapatinib
Endpoint
Progression-free survival and overall survival
NSABP B-47 Trial
Tested
Adjuvant trastuzumab plus chemotherapy
Population
HER2-low (IHC 1+ or 2+/FISH negative) early breast cancer
Comparator
Chemotherapy alone
Endpoint
Invasive disease-free survival
DESTINY-Breast03 Trial
Tested
Trastuzumab deruxtecan
Population
HER2-positive metastatic breast cancer patients previously treated with trastuzumab and a taxane
Comparator
Trastuzumab emtansine (T-DM1)
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis